Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of the transthyretin (TTR) protein that can damage ...

DNA analysis of TTR gene to detect or exclude hereditary transthyretin-related amyloidosis (ATTR). - Serum free light chain assay to detect low grade plasma-cell dyscrasia. - Mass spectrometry for ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Undergo regular eye examinations (especially in patients with familial amyloidosis) due to amyloid deposition behind the lens. Seek genetic counseling to learn about the risks of passing the ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.

Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.

for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...